Business
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
(TheNewswire) November 19, 2025 – TheNewswire - Vancouver, British Columbia, Canad...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n November 19, 2025 –\n \n TheNewswire -\n \n Vancouver,\nBritish Columbia, Canada -  Neurothera Labs Inc. (TSXV: NTLX) (\n \n “\n \n\n Neurothera\n \n ” or the\n \n “\n \n\n Company\n \n ”), a clinical-stage\nbiotech company and an wholly-own subsidiary of SciSparc Ltd. (Nasdaq:\nSPRC), today announced that Clearmind Medicine Inc. (Nasdaq: CMND),\n(FSE: CWY0) has filed an Israeli patent application for an innovative\ncombination therapy of 5-methoxy-2-aminoindane (MEAI) and\nN-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing\ndepression.\n \n\n The patent application results from the ongoing collaboration between\nNeurothera and Clearmind Medicine Inc. This therapy targets depression\ntreatment using the combination of MEAI and PEA. According to the\n \n\n World Health Organization\n \n\n ,\nmajor depressive disorder affects more than 280 million people\nworldwide and remains one of the leading causes of disability, with\nlimited innovative treatment options available.\n \n\n This new filing further expands the joint intellectual property\nportfolio developed through the collaboration. To date, 13 patents\nhave been filed under the partnership, focusing on MEAI and\nN-Acylethanolamines combinations for conditions such as alcohol use\ndisorder, cocaine addiction, obesity and weight loss, and depression.\nPreclinical data supports MEAI’s efficacy in mitigating addictive\nbehaviors while preserving normal natural reward pathways.\n \n\n\n About Neurothera Labs Inc.\n \n\n\n Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical\ncompany focused on developing novel therapeutics for central nervous\nsystem disorders and other underserved health conditions through\ncollaborations and innovative combinations.\n \n\n\n For further information, please contact:\n \n\n\n\n Michal Efraty IR Manager\n \n\n\n\n Neurothera Labs Inc.\n \n\n\n\n\n Telephone: 972-3-7617108\n \n\n\n\n\n Email:\n \n\n\n [email protected]\n \n\n\n\n\n Neither the TSX\nVenture Exchange nor its Regulation Services Provider (as that term is\ndefined in policies of the TSX Venture Exchange)...